Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.
The National Consumer Disputes Redressal Commission (NCDRC) recently upheld negligence charges against a Diagnostic Centre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback